Josh joined NEA in September 2004 as a Venture Partner but has been working closely with NEA since his time as an NEA EIR back in 1995. He is a key member of NEA's healthcare team and focuses primarily on medical devices and consumer health technologies. Josh is also the Founder & Chief Executive Officer of ExploraMed I, II, III, and IV Inc., a series of NEA portfolio medical device incubators based on the West Coast that have created eight companies over the past 20 years. Acclarent, Inc, an ExploraMed II company, was acquired by Johnson & Johnson in 2009. EndoMatrix, Inc. was acquired by C.R. Bard in 1997 and TransVascular, Inc. was acquired by Medtronic in 2003 (both companies were created by ExploraMed I). On-going ExploraMed/NEA ventures include NeoTract, Inc. (created by ExploraMed II), Moximed, Inc. (created by ExploraMed III) and Nuelle, Inc and NC7 (both created by ExploraMed IV). In addition, Josh serves a part-time role on the faculty of the Stanford University Medical School as a Consulting Professor of Medicine and is Co-Founder of Stanford’s Biodesign Innovation Program. Josh serves on the board of directors for ExploraMed II, III and IV, Intrinsic Therapeutics, Inc., NeoTract, Inc., Moximed, Inc., Ceterix, Inc., Nuelle, Inc, NC7 Inc. and Coravin. Prior to NEA, Josh was Founder and Manager of Pfizer’s Strategic Innovation Group. Josh holds over on hundred patents for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery, obesity, orthopedics, women’s health, and urology. He received an MBA from Columbia University, a medical degree from the New York University School of Medicine, and a bachelor's degree in Mechanical Engineering from the Massachusetts Institute of Technology.